Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.48 |
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | PLOD2 | O00469 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PLOD3 | O60568 | 3/20 | 0.46 |
| ▸ | PLOD1 | Q02809 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20690192 | 0.95 | MEN1 (0.53) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL11836186 | 0.93 | MEN1 (0.52) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL7587858 | 0.93 | MEN1 (0.52) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL7581750 | 0.93 | MEN1 (0.52) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL30466754 | 0.93 | MEN1 (0.52) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL1999729 | 0.91 | PLOD2 (0.56) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL4600257 | 0.90 | ERCC5 (0.54) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL1682774 | 0.89 | MEN1 (0.59) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL11946962 | 0.85 | PLOD2 (0.45) | MEN1KMT2ACYP3A4HPGDCES1 | |
| SCHEMBL29596316 | 0.85 | PLOD2 (0.45) | MEN1KMT2ACYP3A4HPGDCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116195372-A | Metal electrode film and method for manufacturing same | CLAP有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| US-11643561-B2 | Process for the preparation of metallic nano-particle layers and their use for decorative or security elements | BASF SE | 2023-05-09 | — | — | US | disclosed |
| WO-2020241498-A1 | LUMINESCENT EUROPIUM COMPLEX | 東ソー株式会社 | 2020-12-03 | — | — | WO | disclosed |
| US-20200230646-A1 | PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORATIVE OR SECURITY ELEMENTS | BASF SE (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | MEN1 4405/4885KMT2A 1794/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.